B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
about
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
B-IGEV (bortezomib plus IGEV) ...... azione Italiana Linfomi (FIL).
@en
B-IGEV (bortezomib plus IGEV) ...... azione Italiana Linfomi (FIL).
@nl
type
label
B-IGEV (bortezomib plus IGEV) ...... azione Italiana Linfomi (FIL).
@en
B-IGEV (bortezomib plus IGEV) ...... azione Italiana Linfomi (FIL).
@nl
prefLabel
B-IGEV (bortezomib plus IGEV) ...... azione Italiana Linfomi (FIL).
@en
B-IGEV (bortezomib plus IGEV) ...... azione Italiana Linfomi (FIL).
@nl
P2093
P2860
P50
P1433
P1476
B-IGEV (bortezomib plus IGEV) ...... dazione Italiana Linfomi (FIL)
@en
P2093
Alessandro Re
Angelagiovanna Congiu
Angelo Michele Carella
Antonella Anastasia
Barbara Botto
Caterina Stelitano
Eleonora Russo
Ercole Brusamolino
Flavia Salvi
Giorgia Annechini
P2860
P304
P356
10.3109/10428194.2016.1140161
P577
2016-02-15T00:00:00Z